Mind Uncharted Explore. Discover. Learn.
Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, has introduced the OPTRELL™ Mapping Catheter with TRUEref™ Technology powered by the CARTO® 3 System in the United States. The OPTRELL™ Mapping Catheter is a high-density diagnostic catheter designed for mapping complex cardiac arrhythmias. It utilizes a fixed array formation with small electrodes to provide high-definition electrophysiological mapping of cases such as persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia. The catheter features 48 electrodes symmetrically distributed across six splines and integrated with the CARTO® 3 System for intelligent insights and high-resolution directional mapping. The tight electrode spacing and small electrodes of the OPTRELL™ Mapping Catheter result in higher signal resolution and enhanced maps of the heart, enabling clinicians to better understand the location of the arrhythmia and develop more effective ablation strategies. The catheter has received FDA 510(k) clearance and is now available in the United States. It will be commercially available in Japan later this year. Biosense Webster aims to provide physicians with innovative tools, integrated with their CARTO® 3 mapping system, to improve the efficiency and effectiveness of procedures and the quality of care for patients.
